Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.